肝细胞癌抗PD-1免疫治疗中应答与不良事件的免疫轨迹解耦
本研究通过飞行时间流式细胞术和单细胞RNA测序分析32例肝细胞癌患者抗PD-1治疗前后外周血样本(n=60),并在独立韩国队列(n=29)中验证。发现CXCR3+CD8+效应记忆T细胞和CD11c+抗原呈递细胞与应答、无进展生存期及免疫相关不良事件均相关,而1型经典树突状细胞与应答相关,2个免疫抑制性CD14+髓系细胞簇与免疫相关不良事件减少相关。小鼠模型中抗PD-1联合抗TNFR2可在不增加不良事件的情况下增强应答。
要点
- CXCR3+CD8+效应记忆T细胞与抗PD-1应答、无进展生存期及免疫相关不良事件均相关。
- 1型经典树突状细胞是与应答相关的特异性抗原呈递细胞。
- 2个免疫抑制性CD14+髓系细胞簇与免疫相关不良事件减少相关。
核心结论
- 本研究识别了肝细胞癌患者抗PD-1免疫检查点阻断临床应答的早期预测因子,并提供了应答与毒性界面上免疫亚群免疫轨迹的机制见解。
- 作者提出一种新的肝细胞癌联合免疫治疗,以在不加剧免疫相关不良事件的情况下增强应答。
研究设计与样本
- 研究分析32例肝细胞癌患者(新加坡队列)抗PD-1治疗前和治疗中的外周血样本(n=60),采用飞行时间流式细胞术和单细胞RNA测序。
- 在独立韩国队列(n=29)中进行流式细胞术验证。
- 对20份治疗前和治疗中肿瘤活检进行批量RNA测序,并使用接受不同免疫治疗组合的小鼠肝细胞癌模型进行机制验证。
- 临床试验注册号:NCT03695952。
主要发现
- 单细胞分析发现CXCR3+CD8+效应记忆T细胞与应答相关(p=0.0004)、与无进展生存期相关(p=0.00079)、与免疫相关不良事件相关(p=0.0034)。
- CD11c+抗原呈递细胞与应答相关(p=0.0255)、与无进展生存期相关(p=0.0015)、与免疫相关不良事件相关(p=0.0125)。
- 1型经典树突状细胞被鉴定为与应答相关的特异性抗原呈递细胞。
- 2个免疫抑制性CD14+髓系细胞簇与免疫相关不良事件减少相关。
- CXCR3+CD8+效应记忆T细胞分析显示应答与免疫相关不良事件特异的细胞间相互作用,据此在小鼠肝细胞癌模型中采用抗PD-1联合抗TNFR2解耦上述效应,结果增强应答而不增加免疫相关不良事件。
临床怎么用
- 作者提出一种新的肝细胞癌联合免疫治疗(抗PD-1联合抗TNFR2),以在不加剧免疫相关不良事件的情况下增强应答;该方案来自小鼠模型研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: While immune checkpoint blockade (ICB) has shown promise in patients with hepatocellular carcinoma (HCC), it is associated with modest response rates and immune-related adverse events (irAEs) are common. In this study, we aimed to decipher immune trajectories and mechanisms of response and/or irAEs in patients with HCC receiving anti-programmed cell death 1 (anti-PD-1) therapy. METHODS: Pre- and on-treatment peripheral blood samples (n = 60) obtained from 32 patients with HCC (Singapore cohort) were analysed by cytometry by time-of-flight and single-cell RNA sequencing, with flow cytometric validation in an independent Korean cohort (n = 29). Mechanistic validation was conducted by bulk RNA sequencing of 20 pre- and on-treatment tumour biopsies and using a murine HCC model treated with different immunotherapeutic combinations. RESULTS: Single-cell analyses identified CXCR3+CD8+ effector memory T (TEM) cells and CD11c+ antigen-presenting cells (APC) as associated with response (p = 0.0004 and 0.0255, respectively), progression-free survival (p = 0.00079 and 0.0015, respectively), and irAEs (p = 0.0034 and 0.0125, respectively) in anti-PD-1-treated patients with HCC. Type-1 conventional dendritic cells were identified as the specific APC associated with response, while 2 immunosuppressive CD14+ myeloid clusters were linked to reduced irAEs. Further analyses of CXCR3+CD8+ TEM cells showed cell-cell interactions specific to response vs. irAEs, from which the anti-PD-1 and anti-TNFR2 combination was harnessed to uncouple these effects, resulting in enhanced response without increased irAEs in a murine HCC model. CONCLUSIONS: This study identifies early predictors of clinical response to anti-PD-1 ICB in patients with HCC and offers mechanistic insights into the immune trajectories of these immune subsets at the interface between response and toxicity. We also propose a new combination immunotherapy for HCC to enhance response without exacerbating irAEs. CLINICAL TRIAL NUMBER: NCT03695952. LAY SUMMARY: Response rates to immune checkpoint blockade (ICB) treatment in hepatocellular carcinoma (HCC) remain modest and adverse events are common. Herein, we identified early predictors of response and gained an in-depth understanding of the immunological mechanisms behind response and adverse events in patients with HCC treated with ICB. We also proposed a new combination immunotherapy for HCC that enhances response without exacerbating adverse events.
引用
- Chuah S, Lee J, Song Y, et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatol. 2022. PMID: 35430299. doi:10.1016/j.jhep.2022.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。